Iuppa Courtney A
(Corresponding author) Clinical Manager and PGY-2 Residency Program Director, Department of Pharmacy, Center for Behavioral Medicine, Kansas City, Missouri,
Ment Health Clin. 2024 Dec 2;14(6):321-327. doi: 10.9740/mhc.2024.12.321. eCollection 2024 Dec.
Two Supreme Court cases in the United States describe the use of involuntary medication in individuals with mental illnesses. In addition to these legal requirements, clinicians must also incorporate ethics into treating these individuals, including the principles of autonomy and beneficence. Current guidelines do not provide specific recommendations for choosing an antipsychotic for a patient with schizophrenia who is being treated involuntarily. However, it is recommended that clinicians use general guidelines for the treatment of schizophrenia as a basis for narrowing down appropriate therapy, which may involve the use of long-acting injectable antipsychotics. Clinical considerations that should be accounted for include past medication trials, potential adverse effects, whether tolerability has been demonstrated, route of administration, dosing interval, requirement for oral overlap, comorbid conditions, patient preference, and access to the medication.
美国最高法院的两个案例描述了对患有精神疾病的个体使用非自愿药物治疗的情况。除了这些法律要求外,临床医生在治疗这些个体时还必须纳入伦理考量,包括自主原则和行善原则。目前的指南并未针对非自愿接受治疗的精神分裂症患者选择抗精神病药物提供具体建议。然而,建议临床医生以精神分裂症治疗的一般指南为基础,缩小合适治疗方法的范围,这可能涉及使用长效注射用抗精神病药物。应考虑的临床因素包括既往用药试验、潜在不良反应、是否已证明耐受性、给药途径、给药间隔、口服重叠的需求、合并症、患者偏好以及药物可及性。